Exelixis, Inc., a biopharmaceutical company, announced that its partner Daiichi Sankyo Company, Limited has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral, non-steroidal, selective mineralocorticoid receptor ... PharmaBiz, 10 hours ago
Daiichi Sankyo launches Phase 3 clinical trial of CS-3150 in Japanese patients with high blood pressure triggering $15M milestone to Exelisis - Seeking Alpha, 1 day ago
Exelixis Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist - Business Wire, 1 day ago
Daiichi Sankyo Company, Limited announced that it has applied for additional indication of denosumab (product name: Pralia subcutaneous injection 60mg syringe) for rheumatoid arthritis-related treatment. Denosumab is the first fully human ...PharmaBiz, 3 days ago Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab FirstWord Pharma, 4 days ago
Daiichi Sankyo Company, Limited and UCB Japan Co., Ltd have announced that they have launched Vimpat tablets 50 mg and 100 mg (generic name: lacosamide; date of approval: July 4, 2016; date of listing in the NHI reimbursement price list in Japan: ...PharmaBiz, 3 weeks ago DAIICHI SANKYO : Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been launched. 4 Traders, 3 weeks ago
Daiichi Sankyo phase 3b ENSURE-AF study of once-daily Lixiana in patients with AF undergoing cardioversion meets primary endpoints
Daiichi Sankyo Company, Limited announced results from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm). The ...PharmaBiz, 3 weeks ago Phase IIIb data backs Daiichi Sankyo's Lixiana in atrial fibrillation patients undergoing cardioversion Pharma Letter, 4 weeks ago Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group PharmaVOICE, 4 weeks ago Daiichi Sankyo Adds Leigh Ann Errico as VP of Human Resources Citybizlist, 1 month ago
| World Heart Federation, 1 week ago
DAIICHI SANKYO : Reports from Daiichi Sankyo Add New Data to Findings in Thrombosis (Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in...
4 Traders, 1 week ago
DAIICHI SANKYO : New Findings on Carboxylic Ester Hydrolases from Daiichi Sankyo Summarized (Identification of a novel boronic acid as a potent, selective, and orally...
4 Traders, 2 weeks ago
ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Ariva.de, 4 weeks ago
More from: PharmaBiz, 4 Traders...and 3 other sources
Daiichi Sankyo and UCB have filed an application for partial amendment of approval toPharma Letter, 1 month ago Daiichi, UCB file application for partial amendment of approval to use lacosamide for epilepsy patients PharmaBiz, 1 month ago DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan 4 Traders, 1 month ago
Daiichi Sankyo has struck a deal to use Veeva Systems ($VEEV) cloud platform to store its R&D files. The agreement sees Daiichi use Veeva Vault to manage electronic trial master files (eTMFs), quality compliance documents and the submission assembly ...FierceBiotech, 1 month ago Daiichi Sankyo Selects Vault To Streamline Submissions, eTMF, And Quality Management BioSpace, 1 month ago Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management SPi World News, 1 month ago Daiichi Sankyo chooses Veeva Vault to streamline submissions, eTMF, and quality management Pharmaceutical Business Review, 1 month ago
Daiichi Sankyo To Present At Late-Breaking Clinical Data For Novel HER2-Targeting Antibody Drug Conjugate In T-DM1 Pre-Treated Breast Cancer
TOKYO , PARSIPPANY, N.J. , and MUNICH , Sept. 27, 2016 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that safety and preliminary efficacy phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody ...BioSpace, 1 hour ago Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer International Business Times, 5 hours ago
More from: , WorldNetDaily...and 3 other sources
Global DNA Gyrase Subunit B (EC 22.214.171.124) Pipeline Review 2016 Featuring Abgentis, AstraZeneca, Daiichi Sankyo Company & Merck & Co. - Research and Markets
has announced the addition of the "DNA Gyrase Subunit B (EC 126.96.36.199) - Pipeline Review, H1 2016" report toBioSpace, 3 weeks ago Global Alzheimers Disease Therapeutics and Diagnostics Market Driven by Rising Aging Population Digital Journal, 1 day ago Hypercholesterolemia Drugs Market Analysis & Forecast to 2020 MyNewsDesk, 1 day ago Pain Management Drugs Market is likely to gain relatively higher over the several coming years MyNewsDesk, 1 day ago
By a News Reporter-Staff News Editor at Drug Week Daiichi Sankyo, Inc. announced the appointment of Marielle Cohard-Radice, MD as Executive Vice President, Global Head of Development, effective September 2, 2016 (see also Pharmaceutical Companies). ...Pharmacy Choice, 4 days ago Daiichi Sankyo appoints Marielle Cohard-Radice Global Head of Development Center Watch, 2 weeks ago Daiichi Sankyo promotes Marielle Cohard-Radice to new global head of development Pharma Letter, 2 weeks ago New Global Head of Development for Daiichi Sankyo PharmExec.com, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!